Atara Biotherapeutics Files 8-K
Ticker: ATRA · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: ATRA
TL;DR
ATRA filed an 8-K, likely routine updates, check for details.
AI Summary
On January 21, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or financial figures detailed in the provided text.
Why It Matters
This 8-K filing indicates Atara Biotherapeutics is providing updates or submitting required documentation to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification without specific details of material events, financial changes, or executive actions.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- January 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-36548 (filing_id) — Commission File Number
- 46-0920988 (tax_id) — IRS Employer Identification No.
- 2380 Conejo Spectrum Street Suite 200 (address) — Principal Executive Offices
- Thousand Oaks (city) — Principal Executive Offices
- California (state) — Principal Executive Offices
- 91320 (zip_code) — Principal Executive Offices
- (805) 623-4211 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Atara Biotherapeutics?
The filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating updates or submissions of required documentation to the SEC.
When was the earliest event reported in this filing?
The earliest event reported is January 21, 2025.
In which state is Atara Biotherapeutics, Inc. incorporated?
Atara Biotherapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Atara Biotherapeutics?
The Commission File Number is 001-36548.
What is the business address of Atara Biotherapeutics?
The business address is 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California, 91320.
Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-21 07:36:00
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Mar
Filing Documents
- atra-20250121.htm (8-K) — 45KB
- atra-ex99_1.htm (EX-99.1) — 17KB
- 0000950170-25-006992.txt ( ) — 177KB
- atra-20250121.xsd (EX-101.SCH) — 24KB
- atra-20250121_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On January 21, 2025, Atara Biotherapeutics, Inc., (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has placed a clinical hold on Atara's active Investigational New Drug (IND) applications. These INDs include the EBVALLO TM (tabelecleucel) program as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), as well as ATA3219, an allogeneic CD19-targeted CAR-T therapy, for the treatment of non-Hodgkin's lymphoma and systemic lupus erythematosus. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated January 21, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atara Biotherapeutics, Inc. Date: January 21, 2025 By: /s/ AnhCo Nguyen AnhCo Nguyen, Ph.D. President and Chief Executive Officer